Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  254 results for ""Antineoplastic Agents, Immunological""

Your Filters

Publisher : springer
Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Impaired cyclin D3 protein degradation contributes to trastuzumab resistance in HER2 positive breast cancer.

  • Authors : Wang Z; Department of Medical Oncology, Cancer Center of Zhejiang University, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310016, Zhejiang, China.; Laboratory of Cancer Biology, Key Lab of Biotherapy in Zhejiang Province, Cancer Center of Zhejiang University, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.

Subjects: Trastuzumab*/Trastuzumab*/Trastuzumab*/pharmacology ; Trastuzumab*/Trastuzumab*/Trastuzumab*/therapeutic use ; Breast Neoplasms*/Breast Neoplasms*/Breast Neoplasms*/drug therapy

  • Source: Medical oncology (Northwood, London, England) [Med Oncol] 2024 Nov 02; Vol. 41 (12), pp. 305. Date of Electronic Publication: 2024 Nov 02.Publisher: Springer Country of Publication: United States NLM ID: 9435512 Publication Model: Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Clinical characteristics, treatment, and outcomes of pembrolizumab-induced uveitis.

  • Authors : Wu Z; College of pharmacy, Changsha Medical University, No. 1501 Leifeng Avenue, Xiangjiang New District, Changsha, Hunan, 410219, China.; Hunan Provincial Key Laboratory of the Research and Development of Novel Pharmaceutical Preparations, Changsha Medical University, Changsha, Hunan, 410219, China.

Subjects: Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/adverse effects ; Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/therapeutic use ; Uveitis*/Uveitis*/Uveitis*/chemically induced

  • Source: Investigational new drugs [Invest New Drugs] 2024 Oct; Vol. 42 (5), pp. 510-517. Date of Electronic Publication: 2024 Aug 14.Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Exceptional Response to Pembrolizumab in HER2-Positive Gallbladder Carcinoma with High Tumor Mutational Burden.

  • Authors : Sasaki A; Department of Gastroenterology, Tokyo Bay Urayasu Ichikawa Medical Center, 3-4-32 Toudaijima, Urayasu, Chiba, 279-0001, Japan. .; Department of Oncology, Tokyo Bay Urayasu Ichikawa Medical Center, 3-4-32 Toudaijima, Urayasu, Chiba, Japan. .

Subjects: Gallbladder Neoplasms*/Gallbladder Neoplasms*/Gallbladder Neoplasms*/drug therapy ; Gallbladder Neoplasms*/Gallbladder Neoplasms*/Gallbladder Neoplasms*/genetics ; Gallbladder Neoplasms*/Gallbladder Neoplasms*/Gallbladder Neoplasms*/pathology

  • Source: Journal of gastrointestinal cancer [J Gastrointest Cancer] 2024 Dec; Vol. 55 (4), pp. 1628-1633. Date of Electronic Publication: 2024 Sep 10.Publisher: Springer Country of Publication: United States NLM ID: 101479627 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

The safety and efficacy of bevacizumab in treatment of recurrent low-grade glioma: a systematic review and meta-analysis.

  • Authors : Habibi MA; Department of Neurosurgery, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. .; Rashidi F

Subjects: Bevacizumab*/Bevacizumab*/Bevacizumab*/therapeutic use ; Bevacizumab*/Bevacizumab*/Bevacizumab*/adverse effects ; Glioma*/Glioma*/Glioma*/drug therapy

  • Source: European journal of clinical pharmacology [Eur J Clin Pharmacol] 2024 Sep; Vol. 80 (9), pp. 1259-1270. Date of Electronic Publication: 2024 May 11.Publisher: Springer Country of Publication: Germany NLM ID: 1256165 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Patterns of brain metastases response to immunotherapy with pembrolizumab.

  • Authors : Mahajan A; Department of Radiology and Biomedical Imaging, Yale University School of Medicine, Neuroradiology Section, CB 30, 333, Cedar St, New Haven, CT, 06510, USA. .; Goldberg SL

Subjects: Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/therapeutic use ; Brain Neoplasms*/Brain Neoplasms*/Brain Neoplasms*/secondary ; Brain Neoplasms*/Brain Neoplasms*/Brain Neoplasms*/drug therapy

  • Source: Journal of neuro-oncology [J Neurooncol] 2024 Sep; Vol. 169 (3), pp. 555-561. Date of Electronic Publication: 2024 Jul 04.Publisher: Springer Country of Publication: United States NLM ID: 8309335 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Report

Chronic polyradiculoneuropathy associated with pembrolizumab for bladder cancer.

  • Authors : Kobayashi Y; Department of Neurology, Nagano Municipal Hospital, 1333-1 Tomitake, Nagano, 381-8551, Japan. .; Iijima K

Subjects: Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/adverse effects ; Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/therapeutic use ; Antineoplastic Agents, Immunological*/Antineoplastic Agents, Immunological*/Antineoplastic Agents, Immunological*/adverse effects

  • Source: Acta neurologica Belgica [Acta Neurol Belg] 2024 Jun; Vol. 124 (3), pp. 1063-1065. Date of Electronic Publication: 2023 Nov 27.Publisher: Springer Country of Publication: Italy NLM ID: 0247035 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Hypofractionated re-irradiation with bevacizumab for relapsed chemorefractory glioblastoma after prior high dose radiotherapy: a feasible option for patients with large-volume relapse.

  • Authors : Tong E; Northern Sydney Cancer Centre, Royal North Shore Hospital, Reserve Rd, St Leonards, NSW, 2065, Australia. .; Horsley P

Subjects: Glioblastoma*/Glioblastoma*/Glioblastoma*/radiotherapy ; Glioblastoma*/Glioblastoma*/Glioblastoma*/drug therapy ; Glioblastoma*/Glioblastoma*/Glioblastoma*/therapy

  • Source: Journal of neuro-oncology [J Neurooncol] 2024 May; Vol. 168 (1), pp. 69-76. Date of Electronic Publication: 2024 Mar 29.Publisher: Springer Country of Publication: United States NLM ID: 8309335 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Clinical outcomes of melanoma brain metastases treated with nivolumab and ipilimumab alone versus nivolumab and ipilimumab with stereotactic radiosurgery.

  • Authors : Tang JD; Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr. , Tampa, FL, USA.; Mills MN

Subjects: Melanoma*/Melanoma*/Melanoma*/pathology ; Radiosurgery*/Radiosurgery*/Radiosurgery*/methods ; Antineoplastic Agents, Immunological*/Antineoplastic Agents, Immunological*/Antineoplastic Agents, Immunological*/therapeutic use

  • Source: Journal of neuro-oncology [J Neurooncol] 2024 Feb; Vol. 166 (3), pp. 431-440. Date of Electronic Publication: 2024 Feb 03.Publisher: Springer Country of Publication: United States NLM ID: 8309335 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Clinical characteristics, diagnosis and management of nivolumab-induced myocarditis.

  • Authors : Li MT; Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou City, 510080, Guangdong Province, China.; He Y

Subjects: Myocarditis*/Myocarditis*/Myocarditis*/chemically induced ; Myocarditis*/Myocarditis*/Myocarditis*/diagnosis ; Myocarditis*/Myocarditis*/Myocarditis*/therapy

  • Source: Investigational new drugs [Invest New Drugs] 2024 Feb; Vol. 42 (1), pp. 116-126. Date of Electronic Publication: 2024 Jan 23.Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Clinical characteristics and prognostic impact of immune checkpoint inhibitor-associated myocarditis in advanced non-small cell lung cancer.

  • Authors : Xu L; The third Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China.; Xu M

Subjects: Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/drug therapy ; Lung Neoplasms*/Lung Neoplasms*/Lung Neoplasms*/drug therapy ; Myocarditis*/Myocarditis*/Myocarditis*/chemically induced

  • Source: Investigational new drugs [Invest New Drugs] 2023 Dec; Vol. 41 (6), pp. 816-824. Date of Electronic Publication: 2023 Oct 30.Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
  • 1-10 of  254 results for ""Antineoplastic Agents, Immunological""